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Available online 30 April 2016Inositol hexakisphosphate kinases (IP6Ks), a family of enzymes found in all eukaryotes, are responsible for the
synthesis of 5-diphosphoinositol pentakisphosphate (5-IP7) from inositol hexakisphosphate (IP6). Three iso-
forms of IP6Ks are found in mammals, and gene deletions of each isoform lead to diverse, non-overlapping phe-
notypes inmice. Previous studies show a facilitatory role for IP6K2 in cell migration and invasion, properties that
are essential for the early stages of tumorigenesis. However, IP6K2 also has an essential role in cancer cell apopto-
sis, andmice lacking this protein aremore susceptible to the development of aerodigestive tract carcinoma upon
treatment with the oral carcinogen 4-nitroquinoline-1-oxide (4NQO). Not much is known about the functions of
the equally abundant and ubiquitously expressed IP6K1 isoform in cell migration, invasion and cancer progres-
sion. We conducted a gene expression analysis on mouse embryonic ﬁbroblasts (MEFs) lacking IP6K1, revealing
a role for this protein in cell receptor-extracellular matrix interactions that regulate actin cytoskeleton dynamics.
Consequently, cells lacking IP6K1 manifest defects in adhesion-dependent signaling, evident by lower FAK and
Paxillin activation, leading to reduced cell spreading and migration. Expression of active, but not inactive IP6K1
reverses migration defects in IP6K1 knockout MEFs, suggesting that 5-IP7 synthesis by IP6K1 promotes cell loco-
motion. Actin cytoskeleton remodeling and cell migration support the ability of cancer cells to achieve their com-
plete oncogenic potential. Cancer cells with lower IP6K1 levels display reduced migration, invasion, and
anchorage-independent growth. When fed an oral carcinogen, mice lacking IP6K1 show reduced progression
from epithelial dysplasia to invasive carcinoma. Thus, our data reveal that like IP6K2, IP6K1 is also involved in
early cytoskeleton remodeling events during cancer progression. However, unlike IP6K2, IP6K1 is essential for
4NQO-induced invasive carcinoma. Our study therefore uncovers similarities and differences in the roles of
IP6K1 and IP6K2 in cancer progression, and we propose that an isoform-speciﬁc IP6K1 inhibitor may provide a
novel route to suppress carcinogenesis.
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Inositol pyrophosphates are a class of high-energy signaling
molecules characterized by the presence of pyrophosphate and
monophosphate substitutions on the inositol ring [1–4]. They participate
in many cellular functions by binding speciﬁc proteins or by transferring
their β phosphate to prephosphorylated serine residues to bring about
serine pyrophosphorylation [3–6]. Themost abundant inositol pyrophos-
phate in mammals, 5-diphosphoinositol pentakisphosphate (5-PP-IP5 or
5-IP7) is synthesized from inositol hexakisphosphate (IP6) by inositol
hexakisphosphate kinases (IP6Ks) [7,8]. IP6Ks can also synthesize 5-PP-
IP4 from IP5 [8,9]. IP6Ks are found in all eukaryotes, with lower organisms
such as yeast, slime mold and Drosophila possessing a single IP6K, andthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tinct genes [10]. Amongst these, IP6K1 and IP6K2 are expressed in several
tissues [7], whereas IP6K3 shows high expression only in the cerebellum
[9].
IP6K1 promotes insulin release from pancreatic β cells [11], and par-
ticipates in maintaining genome integrity via homologous recombina-
tion mediated DNA repair [12] and nucleotide excision repair [13].
Mice lacking IP6K1 display reduced serum insulin [14], male infertility
[14], decreased susceptibility to a thrombotic challenge [15], enhanced
Akt signaling [16], and reduced social behavior [17]. IP6K2 has been
shown to promote tumor cell growth and migration by antagonizing
liver kinase B1 [18]. Conversely, IP6K2 also enhances p53-mediated ap-
optosis in cancer cells so that the loss of IP6K2 results in reduced apo-
ptosis [19,20], and IP6K2 knockout mice are more susceptible to 4-
nitroquinoline-1-oxide (4NQO) induced aerodigestive tract carcinoma
[21]. Recently, mice lacking IP6K3 were shown to display defects in
motor function due to altered cytoskeletal architecture in cerebellar
Purkinje cells [22].
Interaction of cells with the extracellular matrix triggers adhesion-
dependent signaling pathways that play an important role in the regu-
lation of cell growth, survival, cell migration and invasion - processes
that are crucial in the pathophysiology of cancer [23]. Upon exposure
to a carcinogen, epithelial cells display hyperproliferation and undergo
structural and biochemical changes that aid in their migration and inva-
sion into the underlying basementmembrane [24,25]. Eventually, these
tumor cells can invade blood and lymphatic vessels to metastasize to
other tissues.
To explore the biological functions of IP6K1, we conducted a
microarray-based gene expression analysis on mouse embryonic ﬁbro-
blasts (MEFs) derived from Ip6k1−/− mice. Interestingly, cells lacking
IP6K1 showed down-regulated expression of several genes involved in
mediating cell–matrix interaction and downstream signaling. Conse-
quently, cells with reduced IP6K1 expression displayed diminished mi-
gration and invasion properties. Contrary to observationsmade in Ip6k2
knockout mice, deletion of Ip6k1 led to reduced development of inva-
sive epithelial carcinoma upon chronic exposure of the aerodigestive
tract to 4NQO. Therefore, our data shows that IP6K1 expression is re-
quired for cancer cells to achieve their complete oncogenic potential.
2. Materials and methods
2.1. Cell lines
All cell lines were grown at 37 °C in a humidiﬁed incubator with 5%
CO2. Ip6k1+/+ and Ip6k1−/−MEFs [14] and Ip6k1−/−MEFs expressing ki-
nase active or inactive variants of IP6K1 [12] were cultured in Dulbecco's
modiﬁed Eagle'smedium(DMEM, Life Technologies) supplementedwith
10% fetal bovine serum (FBS, Life Technologies), 1 mM L-Glutamine (Life
Technologies), 100 U/mL penicillin, and 100 μg/mL streptomycin (Life
Technologies). HeLa and HCT116 cell lines were used for stable knock-
down of IP6K1 expression. Lentiviral vectors (pLKO.1) encoding either a
non-targeting shRNA (SHC016, Sigma-Aldrich) or two speciﬁc sequences
of shRNA directed against human IP6K1 (TRC0000013508, designated
shIP6K1–1 and TRC0000196808, designated shIP6K1–4, Sigma-Aldrich),
were co-transfected with VSV-G and psPAX2 (a gift from Didier Trono,
Addgene plasmid #12260) plasmids into the HEK293T packaging cell
line, using polyethylenimine reagent (Polysciences Inc.) and incubated
at 37 °C with 5% CO2 to generate lentiviral particles. After 48 h, viral par-
ticles were harvested from the culture supernatant by ﬁltering through a
0.45 μm syringe ﬁlter unit. Viral particles harboring either non-targeting
control or IP6K1 directed shRNA were used to infect HeLa or HCT116
cell lines following treatment with polybrene (8 μg/mL, Sigma-Aldrich)
for 2 h. After 48 h, transduced cells were selected with 2 μg/mL puromy-
cin (Sigma-Aldrich) by changing the medium twice a week. Once cells
reached optimal growth, polyclonal populations were maintained in
complete DMEM supplemented with 1 μg/mL puromycin (Sigma-Aldrich). Knockdown was conﬁrmed by immunoblot analysis with an
IP6K1 speciﬁc antibody.
2.2. Mice
All animal experiments were conducted as per guidelines provided
by the Committee for the Purpose of Control and Supervision of Exper-
iments on Animals, Ministry of Environment, Forest, and Climate
Change, Government of India, and these experiments were approved
by the Institutional Animal Ethics Committee (Protocol numbers PCD/
CDFD/02-version 2 and PCD/CDFD/08). Mice used for this study were
housed in the Centre for DNA Fingerprinting and Diagnostics animal fa-
cility located within the premises of Vimta Labs, Hyderbad. Ip6k1+/−
heterozygous mice were bred to generate age and sex matched
Ip6k1+/+ and Ip6k1−/− littermates for experiments. Foxn1nu mice
were generated by breeding homozygous males with heterozygous
females.
2.3. Reagents and antibodies
Primary antibodies used for immunoblot analysis were obtained from
the following sources: Rabbit anti-IP6K1 (HPA040825, Sigma-Aldrich),
goat anti-IP6K1 (sc-10419, Santa Cruz Biotechnology), rabbit anti-
phosphoFAK (Tyr397) (3283, Cell Signaling Technology), rabbit anti-
FAK (3285, Cell Signaling Technology), rabbit anti-phosphoPaxillin
(Tyr118) (2541, Cell Signaling Technology), mouse anti-Paxillin
(610051, BD Biosciences), mouse anti-actin (ab3280, Abcam), mouse
anti-GAPDH (G8795, Sigma-Aldrich), mouse anti-E Cadherin (14472S,
Cell Signaling Technology), and rabbit anti-vimentin (ab92547, Abcam).
Reagents used for cell spreading: ﬁbronectin (F2006, Sigma-Aldrich),
methyl cellulose (Sigma-Aldrich) and ﬂuorophore conjugated phalloidin
(Molecular Probes Inc.). Propylene glycol (151957, MP Biomedicals) was
used to dissolve the oral carcinogen 4-Nitroquinoline-1-Oxide (4NQO,
Sigma-Aldrich). All other reagents, unless otherwise stated, were obtain-
ed from Sigma-Aldrich.
2.4. Gene expression microarray
MEFs derived from two Ip6k1+/+ and Ip6k1−/− embryos each were
immortalised by the expression of SV40 large T antigen [14] and stored
in liquid nitrogen. Thawed cells were passaged twice, harvested by
trypsinization, and their genotype was re-conﬁrmed by PCR as de-
scribed in [14]. 107 cells were resuspended in 100 μL PBS and 5 volumes
of RNAlater (Sigma-Aldrich). Total RNAwas extracted using the RNeasy
Mini Kit (Qiagen). The samples were labeled using the Agilent Quick-
Amp labeling Kit. 500 ng of each sample was incubated with reverse
transcription mix at 40 °C and converted to double stranded cDNA
primed by oligonucleotide dT with a T7 polymerase promoter. cRNA
was generated by in vitro transcription of the double stranded cDNA
at 40 °C, and the dye Cy3 CTP (Agilent) was incorporated during this
step. 600 ng of Cy3 labeled RNA samples were fragmented and hybrid-
ized using the Gene Expression Hybridization kit (Agilent). Hybridiza-
tion onto the Agilent-014868 Whole Mouse Genome Microarray
4x44K (G4122F) was carried out in Agilent's Surehyb Chambers at
65 °C for 16 h. The hybridized slides were washed using Gene Expres-
sion wash buffers (Agilent), and scanned using the Agilent Microarray
Scanner (G2505C) at 5 μm resolution. Data was extracted using Feature
Extraction software and normalized usingGeneSpringGX (75th percen-
tile shiftmethod). Data are presented as the average fold change in gene
expression in the two Ip6k1−/−MEF lines compared with the average
expression for that gene in two Ip6k1+/+ MEF lines.
Gene expression quantiﬁcationwas carried out by reverse transcrip-
tion quantitative real time PCR (RT-qPCR). Brieﬂy, total cellular RNA
was isolated from single cell derived Ip6k1+/+ and Ip6k1−/− MEFs
using TRIzol reagent (Invitrogen) followed byRNeasyMini Kit (Qiagen).
2 μg of total RNA was used for ﬁrst strand cDNA synthesis by reverse
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with oligonucleotide dT primers. qPCR was performed using gene spe-
ciﬁc primers on the ABI 7500 Real-Time PCR System (Applied
Biosystems) with MESA GREEN qPCR MasterMix Plus for SYBR® Assay
Low ROX (Eurogentec) for detection. Each sample was run in duplicate.
The primer sequences are listed in Supplemental Table S1 in the online
version at http://dx.doi.org/10.1016/j.cellsig.2016.04.011.. The differ-
ence in gene expression was calculated using the fold change (ΔΔCt
method) [26]. ΔCt is the Ct value for the gene of interest normalized to
the Ct value of the respective GAPDH control in both Ip6k1+/+ and
Ip6k1−/− MEFs. ΔΔCt values were calculated as a relative change in
ΔCt of the target gene in Ip6k1−/−with respect to Ip6k1+/+ MEFs. Fold
changes were expressed as 2−ΔΔCt for up-regulated genes and the neg-
ative reciprocal of the fold change for down-regulated genes (where
2−ΔΔCt b 1).
2.5. Cell adhesion
Cell adhesion assays were performed as described previously [27]
with slight modiﬁcations. Brieﬂy, 5 × 104 cells were seeded per well
into ﬁbronectin (2 μg/mL) coated 24 well plates. Cells were allowed to
adhere for the indicated time. At each time point, unadhered cells
were washed away with media and fresh medium was added to the
wells. After 5 h,wellswerewashedwith PBS and stainedwith 0.2% crys-
tal violet (in 2% ethanol) for 10 min. Wells were thoroughly washed
with PBS and cells were lysed by shaking in 1% SDS. Absorbance was
monitored at 595 nm using an EnSpire multimode plate reader
(PerkinElmer).
2.6. Cell spreading
Cell spreading assayswere done as described previously [28]. Brieﬂy,
cells were cultured in complete medium (10% FBS) or subjected to
serum starvation (0.2% FBS for 12–14 h), trypsinized, counted using a
hemocytometer, and held in suspension in the same medium contain-
ing 1% methylcellulose at 37 °C and 5% CO2. After 90 min, cells were
washed twicewithmedium to removemethylcellulose. Cell suspension
equivalent to 105 cells was plated onto each ﬁbronectin (2 μg/mL) coat-
ed coverslip and allowed to spread for 15min or 24 h in serumdepleted
(0.2% FBS) or completemedium. At each time point, the coverslips were
ﬁxed with 3.5–4% paraformaldehyde for 20 min, followed by 3 washes
with PBS. Fixed cells were stained with ﬂuorophore-conjugated
phalloidin (Alexa Fluor 488 or rhodamine) for 45 min, followed by
DAPI staining for 2 min. Cover slips were mounted onto glass slides
using Fluoromount G (Southern Biotech) or Vectashield (Vector Labs),
and imaged using an LSM 710 laser confocal-anisotropy microscope
(Zeiss, Zen acquisition software, 40 × 1.3 N.A. objective) for 15 min
spreading, or LSM 510 laser confocal microscope (Zeiss, LSM acquisition
software, 63× 1.4 N.A. objective) for 24 h spreading. To measure cell
spread area, images captured at identical zoom settings were analyzed
using the Image J software (NIH) as follows: threshold values were set
to deﬁne the cell edge and a mask was then created for each cell to
get the total cell area (with arbitrary units) within the mask. For 24 h
spreading, the exact spread area was calculated based on pixel dimen-
sions during image acquisition.
2.7. Western blot analysis
Cells were seeded in six well plates. After attaining optimal growth,
cell lysates were prepared by scraping cells in 1× Laemmli buffer and
samples were processed by standard Western blot techniques. To detect
FAK and Paxillin activation, 2 × 106 cells (6 × 105 cells per time point)
were held in suspension in completemedium containing 1%methylcellu-
lose for 90min (Susp), and replated on ﬁbronectin (2 μg/mL) coated sur-
faces for 20 min (+FN) or for 4 h (SA - stably adherent). Cells at each
time point were lysed in 1× Laemmli buffer and subjected toimmunoblotting. Membranes were probed with speciﬁc antibodies and
detected using the ECL detection system (GE Healthcare).
Chemiluminiscence was detected using the LAS4000 (GE Healthcare) or
FlourChem E (Protein Simple) documentation system. Densitometry
analysis of bands was done using ImageJ documentation software (Fiji)
or the multiplex band analysis tool in AlphaView software (Protein
Simple).
2.8. Cell proliferation assay
Cells were seeded in 24 well plates at 10% conﬂuence in triplicates
and allowed to grow for different lengths of time. Spentmediumwas re-
placed with freshmedium every 48 h. Cell viability was analyzed by the
MTT assay at each time point [12]. Absorbance values at 570 nm were
measured using the EnSpire multimode plate reader (PerkinElmer).
Doubling timewas determined by conducting linear regression analysis
using GraphPad Prism 5.
2.9. Transwell migration and invasion assay
Transwell migration and invasion assays were conducted as de-
scribed previously [18]. Brieﬂy, transwell inserts (24 well, 8 μm pore
size, Costar, Corning) with or without pre-coated matrigel (BioCoat
Matrigel invasion chamber, 24 well, 8 μm pore size, Corning) were
used to conduct the migration and invasion assays respectively.
5 × 104 (for migration assay) or 1 × 105 (for invasion assay) cells
were suspended in 200 μL of DMEM medium containing 1% FBS and
added to the upper chambers while the lower chambers were ﬁlled
with 700 μL of complete DMEM containing 10% FBS to serve as the che-
motactic agent. Cells were incubated at 37 °C with 5% CO2 for 18 h
(MEFs) and 24 h (HeLa and HCT116 cells) to allow migration and inva-
sion. At the indicated time, cells on the upper surface of the ﬁlters were
removed using cotton swabs. Cells that migrated to the lower surface of
the ﬁlter were rinsed with PBS twice, ﬁxed with 4% paraformaldehyde
for 15 min, and stained with DAPI. Images were acquired using an
epiﬂuorescence inverted microscope (Olympus lX51, Image-Pro AMS
6.0 acquisition software, 20× 0.45 N.A. objective). The number of cells
migrated to the lower surfacewasquantiﬁed by counting the total num-
ber of DAPI positive nuclei in at least 10 random ﬁelds. For the invasion
assay, the total number of cells invaded was normalized to non-
targeting control cells and expressed as percentage invasion.
2.10. Scratch wound healing assay
Scratch wound healing assay was performed as described previ-
ously [18].Cells were seeded in 6 well plates to attain conﬂuence.
On the next day, a scratch was made on the conﬂuent monolayer cul-
ture using a 200 μL pipette tip. Wound closure was monitored during
the indicated time points. Images were acquired using a Zeiss phase
contrast inverted microscope (ProgRes CapturePro v2.8 acquisition
software, 5× 0.12 N.A. objective). The area of wound closure was an-
alyzed using ImageJ software, and the data was plotted as total area
covered in square μm.
2.11. Analysis of cellular inositol polyphosphates
Soluble inositol polyphosphate levels were analyzed as previously
described [29]. 2.5 × 105 cells cultured as described in Section 2.1
were labeledwith 60 μCi [2−3H]myo-inositol (MP Biomedicals, specif-
ic activity 23.75 Ci/mmol) for 4 days and subjected to extraction of sol-
uble inositol phosphates [29]. The lipid inositol fractionwas extracted as
described earlier [14] and counted using a liquid scintillation analyzer
(Tri-Carb 2910 TR, Perkin Elmer). Soluble inositol phosphates were re-
solved by HPLC on a Partisphere SAX column (4.6 mm × 125 mm,
Whatman) using a gradient of Buffer A (1 mM EDTA) and Buffer B
[1mM EDTA and 1.3 M (NH4)2HPO4 (pH 3.8)] as follows: 0–5 min,
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1 mL fractions containing soluble inositol phosphates were counted,
normalized to the total lipid count, and plotted using GraphPad Prism 5.
2.12. Anchorage-independent cell growth
Anchorage independent cell growth was assessed as previously de-
scribed [30]. Brieﬂy, 16,000 cells were suspended in 0.3% top agar and
plated in duplicates in 6 well plates containing a 0.5% base agar layer.
Plates were incubated at 37 °C and 5% CO2 for 28 days. After every
2 days, 0.5 mL medium was applied to the top agar to prevent it from
drying out. After 28 days, colonies were stained with 0.005% crystal vi-
olet (in 2% ethanol), imaged using an AlphaImager (Alpha Innotech),
and the number of colonies was determined using ImageJ software. Im-
ages of stained colonies were acquired using a Zeiss phase contrast
inverted microscope (ProgRes CapturePro v2.8 acquisition software,
5× 0.12 N.A. objective). Area of the colonies was determined using
ImageJ software.
2.13. In vivo xenograft model
In vivo xenograft studies were performed as previously described
[18]. Approximately 2 × 106 HCT116 cells stably expressing NT or
shRNA against IP6K1 were injected subcutaneously into either ﬂank of
6 week old homozygous Foxn1nu athymic nude mice (n = 8 mice).
Mice were euthanized 4 weeks after injection and tumors were surgi-
cally excised and weighed.
2.14. Carcinogenesis study in Ip6k1 knockout mice
Carcinogenesis studies were conducted as described previously
for Ip6k2−/− mice [21]. Brieﬂy, the carcinogen, 4NQO stock solution
(5 mg/mL) was prepared fresh in propylene glycol every week.
Four week old mice [11 Ip6k1+/+ (5 male, 6 female) and 9
Ip6k1−/− (4 male, 5 female)] were exposed to 4NQO (100 μg/mL)
in their drinking water. Mice were allowed free access to drinking
water containing carcinogen, and the water was changed every
week. After 24 weeks, mice were euthanized by CO2 inhalation and
a complete necropsy was performed. Tissues from the aerodigestive
tract (tongue, esophagus, stomach and duodenum)were ﬁxed in for-
malin and parafﬁn embedded sections were stained with hematoxy-
lin and eosin (H&E) to examine the lesions by light microscopy. Mice
showing any characteristics of weight loss or dehydration before
24 weeks were euthanized and examined for lesions. Images were
acquired using a bright ﬁeld light microscope (Nikon ECLIPSE Ni,
NIS Elements acquisition software, 20× 0.5 N.A. objective). During
pathological examination, the lesions observed in the various tissues
were categorized into hyperplasia, dysplasia and invasive carcinoma.
Hyperplasia was deﬁned as an increase in the layers or thickening of
the epithelium with hyperkeratinization. Dysplasia was deﬁned as
loss of epithelial cell polarity, nuclear pleomorphism and abnormal
mitoses conﬁned to the epithelium. Invasive carcinoma was deﬁned
as invasion of dysplastic cells or lesions into subepithelial tissues
such as submucosa and muscle.
2.15. Data analysis
Statistical analysis was performed using GraphPad Prism 5. Data are
presented asmean± SEM. The difference between two groups was an-
alyzed using either a two-tailed Student's t-test or a nonparametric
two-tailedMann-Whitney test, as appropriate. The differences between
multiple groups were analyzed by one way ANOVA, using Tukey's mul-
tiple comparison test. P ≤ 0.05was considered as statistically signiﬁcant.
The cell numbers used to obtain quantitative data (n) and thenumber of
independent experiments performed is indicated in the respective ﬁg-
ure legends.3. Results
3.1. Loss of IP6K1 leads to dysregulation of genes involved in cell
surface-extracellular matrix signaling
To uncover novel biological functions of IP6K1, we performed a gene
expression microarray analysis on mouse embryonic ﬁbroblast (MEF)
lines derived from two Ip6k1+/+ and Ip6k1−/− embryos each [14]. Ap-
plying a cutoff of 2-fold difference in expression in Ip6k1−/− compared
with Ip6k1+/+ MEFs, we observed 374 up-regulated and 888 down-
regulated genes (Supplemental Table S2 in the online version at
http://dx.doi.org/10.1016/j.cellsig.2016.04.011.). To validate the data
from the microarray, we selected 23 up- and 25 down-regulated
genes spanning a wide range of fold changes in gene expression, and
conducted RT-PCR analysis to compare transcript levels in Ip6k1+/+
and Ip6k1−/−MEFs. Amongst the 48 genes tested 41 transcripts showed
the same trend by RT-PCR andmicroarray (Fig. 1A–B), implying that the
majority of dysregulated genes identiﬁed by microarray analysis are
likely to display differential transcript levels in Ip6k1−/− compared
with Ip6k1+/+ MEFs.
The lists of up- and down-regulated genes were subjected to Func-
tional Annotation Clustering using the DAVID tool [31] (Supplemental
Table S2 in the online version at http://dx.doi.org/10.1016/j.cellsig.
2016.04.011.). We found signiﬁcant enrichment of Gene Ontology
(GO) term clusters with an enrichment score larger than 2 (P-
value ≤ 0.01) only in the down-regulated gene list (Fig. 1C). In this
gene list, enriched cellular component (CC) GO terms include proteins
located in the extracellular region and cell junctions, and enriched bio-
logical process (BP) GO terms include cell adhesion, cell-cell signaling
and locomotory behavior. The enrichment of these GO terms suggests
that processes involving cell receptor and extracellular matrix interac-
tions such as cell adhesion, spreading and migration may be
deregulated in the absence of IP6K1.
3.2. IP6K1 is required for adhesion dependent cell spreading
Integrins are transmembrane heterodimeric receptors that engage
with the extracellular matrix (ECM) to activate intracellular signaling
at focal adhesions, leading to actin cytoskeleton remodeling [32].
There is extensive cross-talk of integrin-mediated signaling with
growth factor-mediated signaling pathways, so that on loss of adhesion
several growth factor dependent signaling pathways are also down-
regulated [33]. Subsequent readhesion of cells restores signaling to
drive cytoskeletal remodeling and cell spreading [34]. To examine the
effects that IP6K1 has along this pathway, we studied the consequence
of its depletion on cell spreading. We held MEFs in suspension in the
presence of high (10% serum) or low serum (0.2% serum) growth fac-
tors, and replated them on the ECM protein ﬁbronectin, also in high or
low serum conditions, allowing them to adhere and spread. Spreading
of cells observed 15 min after replating was signiﬁcantly reduced in
Ip6k1−/− MEFs, in the presence of both high and low serum (Fig. 2A–
D). This suggests that IP6K1 is involved in adhesion-dependent signal-
ing and resulting cytoskeletal remodeling that controls cell spreading,
and that IP6K1 acts upstream of integrin-growth factor synergies. All
subsequent assays were conducted in the presence of 10% serum, so
that cell growth and other growth factor dependent pathways were
not compromised.
Reduced cell spreading in Ip6k1−/−MEFs could result from defects
in integrin engagement with ﬁbronectin. To rule out this possibility,
we plated cells on ﬁbronectin and monitored their adhesion to the
ECM over different periods of time. Adhesion to ﬁbronectinwas compa-
rable in Ip6k1+/+ and Ip6k1−/−MEFs from 5 min to 5 h (Fig. 2E), sug-
gesting that integrin-mediated adhesion is not signiﬁcantly altered by
IP6K1 depletion. Autophosphorylation of focal adhesion kinase (FAK)
is triggered by integrin binding to ﬁbronectin and is an early signaling
event supporting cytoskeletal remodeling during cell spreading
Fig. 1. Deletion of Ip6k1 in mice alters gene expression. RT-qPCR analysis of 23 up-regulated (A) and 25 down-regulated (B) genes each, to validate the gene expression microarray
conducted on Ip6k1+/+ and Ip6k1−/−MEFs. Values indicate the fold change in transcript levels in Ip6k1−/−MEFs normalized to Ip6k1+/+ MEFs. The microarray data is the average fold
change in gene expression in two independent Ip6k1−/− MEF lines compared with the average expression for that gene in two independent Ip6k1+/+ MEF lines. RT-qPCR data
(mean ± range from two independent experiments) is the fold change in gene expression in a single-cell derived Ip6k1−/−MEF line compared with a single-cell derived Ip6k1+/+
MEF line. These cell lines were used for further studies. The dashed lines in the graphs mark the range from −1 to +1, the region of no change in gene expression. (C) The list of
down-regulated genes in Ip6k1−/−MEFs was subjected to Functional Annotation Clustering of Gene Ontology (GO) terms using the DAVID tool. The graph depicts clusters of Cellular
Component (CC), Biological Process (BP) and Molecular Function (MF) GO terms with a group enrichment score ≥ 2 (P ≤ 0.01).
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allowed to grow on ﬁbronectin for 4 h (stably adherent cells) (Fig. 2F–G).
When MEFs were held in suspension for 90 min, FAK phosphorylation
was down-regulated in both Ip6k1+/+ and Ip6k1−/−MEFs, with greater
down-regulation seen in Ip6k1−/− MEFs (Fig. 2F–G). When cells were
subsequently allowed to spread on ﬁbronectin for 20min, FAK activation
was lower in Ip6k1−/− comparedwith Ip6k1+/+MEFs (Fig. 2F–G). Paxillinis a scaffold protein that is phosphorylated by FAK and recruits many reg-
ulatory and structural proteins required for cytoskeletal reorganization
during cell spreading [37–39]. Phosphorylation changes in Paxillin mir-
rored those seen in FAK. Ip6k1+/+ MEFs showed an increase in Paxillin
phosphorylation on Tyr118 after plating on ﬁbronectin, whereas the ex-
tent of phospho-Paxillin was reduced in Ip6k1−/−MEFs (Fig. 2F and H).
This indicates that the activation of adhesion-dependent signaling is
Fig. 2. IP6K1 regulates cell spreading on ﬁbronectin. (A) Spreading of Ip6k1+/+ and Ip6k1−/−MEFs 15min after plating on ﬁbronectin in the presence of 10% serum, visualized by staining
with Alexa Fluor 488-conjugatedphalloidin. Scale bars represent 50 μm(left panel) and 10 μm(right panel). (B)Quantiﬁcation of (A); the bar graph shows the cell spread area after 15min
inMEFs of the indicated genotypes. Data representsmean± SEM(n=438 and 474 cells respectively for Ip6k1+/+ and Ip6k1−/−MEFs), compiled from four independent experiments and
was analyzed using the non-parametric two-tailedMann-Whitney test. (C) Spreading ofMEFs 15min after plating on ﬁbronection in the presence of 0.2% serum, visualized as in (A). Scale
bars represent 50 μm. (D) Quantiﬁcation of (C); the bar graph shows the cell spread area after 15min inMEFs of the indicated genotypes. Data representsmean± SEM (n= 216 and 230
cells respectively for Ip6k1+/+ and Ip6k1−/−MEFs), compiled from three independent experiments and was analyzed as in (B). (E) Adhesion of MEFs to a ﬁbronectin-coated surface was
monitored by crystal violet staining of adhered cells after washing off the unattached cells. The bar graph shows the crystal violet absorbance values at the indicated time points. Data are
mean ± SEM from three independent experiments, analyzed by a two tailed unpaired Student's t-test. (F) Immunoblot analysis of FAK and Paxillin activation in MEFs conducted as de-
scribed in theMethods section.Membraneswere probedwith the indicated antibodies and actinwas used as the loading control. (G, H) Quantiﬁcation of pFAK (G) and pPaxillin (H) levels
from panel F. Data are mean ± range from two independent experiments. (I) Representative images showing cell morphology 24 h after spreading on ﬁbronectin visualized by staining
with rhodamine-conjugated phalloidin. Scale bars represent 50 μm(left panel) and 20 μm(right panel showing an enlarged image from the same ﬁeld). (J) Quantiﬁcation of (I); bar graph
shows the cell spread area 24 h after plating. Data represents mean ± SEM (n= 20 and 22 cells respectively for Ip6k1+/+ and Ip6k1−/−MEFs) compiled from two independent exper-
iments and was analyzed using the non-parametric two-tailed Mann-Whitney test. ***P ≤ 0.001; *P ≤ 0.05; ns, not signiﬁcant, P N 0.05.
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nectin for 24 h, Ip6k1−/−MEFs were still found to marginally lag in their
spread area compared with Ip6k1+/+ MEFs (Fig. 2I–J). However, the two
cell types showed no obvious differences in cell morphology and the pat-
tern of F-actin staining by rhodamine-phalloidin (Fig. 2I). These data indi-
cate that IP6K1 is required for early events in integrin-dependent
signaling and cytoskeleton remodeling that are involved in cell spreading,
while it is dispensable formaintenance of the actin cytoskeleton structure
under steady state conditions.
3.3. IP6K1 modulates migration in ﬁbroblasts
Integrin- and growth factor-dependent pathways that regulate cell
spreading are also involved in cellmigration [33,34,37]. This, considered
with the down-regulation of genes involved in cell locomotory behavior
in Ip6k1−/−MEFs (Fig. 1C, Supplemental Table S2 in the online version
at http://dx.doi.org/10.1016/j.cellsig.2016.04.011.), suggests that IP6K1
may inﬂuence cellmigration and chemotaxis. To test this,wemonitored
the migration of MEFs plated on permeable membranes in low serumconditions towards serum-rich medium over 18 h. Loss of IP6K1 led to
a signiﬁcant reduction in the number of cells that are able to cross the
membrane in response to the growth factor gradient (Fig. 3A and C).
We also monitored the collective migration of conﬂuent ﬁbroblast
monolayers in an in vitro wound healing assay in the presence of
serum growth factors, and noted that wound closure is substantially re-
duced in Ip6k1−/−MEFs (Fig. 3B and D).
The IP6 kinases have been shown to participate in different cellular
pathways via the production of inositol pyrophosphates or via interac-
tion with other proteins independent of their enzymatic activity [8].
To determinewhether the inﬂuence of IP6K1 on chemotaxis andmigra-
tion is dependent upon its inositol pyrophosphate synthesis activity, we
tested Ip6k1−/−MEFs expressing either an active or catalytically inac-
tive form of IP6K1 [12]. Active IP6K1 expressionwas able to restore che-
motaxis towards high serum in Ip6k1−/−MEFs, whereas the expression
of inactive IP6K1 failed to do so (Fig. 3A and C). A similar effectwas seen
on the defect in collective cell migration, which was completely re-
versed by expression of active IP6K1, but not by the inactive enzyme
(Fig. 3B and D). These data show that IP6K1 can indeed regulate
Fig. 3. Inositol pyrophosphates modulate cell migration in MEFs. (A) MEFs of the indicated genotypes were seeded in transwell inserts and incubated for 18 h with serum-depleted
medium in the upper chamber and complete medium in the lower chamber. Cells that migrated towards serum-rich medium were visualized by staining with DAPI. Scale bars
represent 50 μm. (B) Collective cell migration was monitored by a scratch wound healing assay conducted on MEFs of the indicated genotypes. Representative images are shown for
the indicated time points. Black lines overlaid on the images mark the edges of the wound. (C) Quantiﬁcation of (A); the bar graph shows number of cells migrated per ﬁeld after 18 h.
Data represents mean ± SEM (n = 65 and 76 ﬁelds respectively for Ip6k1+/+ and Ip6k1−/−MEFs; n = 77 and 90 ﬁelds respectively for Ip6k1−/−MEFs expressing active or inactive
forms of IP6K1) compiled from two independent experiments and was analyzed using one-way ANOVA with Tukey's multiple comparison test. (D) Quantiﬁcation of area covered in
(B); data represents mean ± SEM from three independent experiments and was analyzed using one-way ANOVA with Tukey's multiple comparison test. ***P ≤ 0.001; *P ≤ 0.05; ns,
not signiﬁcant, P N 0.05.
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thesize inositol pyrophosphates.
3.4. Depletion of IP6K1 impairs migration in cancer cells
To determinewhether the effect of IP6K1 on chemotaxis andmigra-
tion extends to cancer cells, we generated HCT116 and HeLa cell lines
expressing shRNA directed against human IP6K1. Of the ﬁve different
shRNA constructs tested, we observed N30% knockdown in IP6K1 ex-
pression with only two constructs, which we called shIP6K1–1 and
shIP6K1–4. These shRNA targeted IP6K1 expression with varying efﬁ-
ciency inHeLa andHCT116 cell lines.While shIP6K1–4 resulted in an ap-
proximately 80% decrease in IP6K1 expression in HeLa cells compared
with control cells expressing non-targeting (NT) shRNA (Fig. 4A–B),
the same construct showed poor knockdown efﬁciency (approximately
40%) in HCT116 cells (Fig. 4A and C). shIP6K1–1 expression led to an ap-
proximately 60% knockdown in both cell lines (Fig. 4A-C). Therefore,
shIP6K1–1 expressing HCT116 cells and shIP6K1–4 expressing HeLa
cells were used for further analysis. Analysis of the soluble inositol
polyphosphate proﬁle in HeLa cells expressing shIP6K1–4 revealed a
substantial reduction in the level of the inositol pyrophosphate PP-IP4,
but no change in the level of its precursor, IP5. Interestingly, there was
a marginal reduction in IP6, but no signiﬁcant difference in the level of
its inositol pyrophosphate product, IP7 (Fig. 4D). Conversely, HCT116
cells depleted for IP6K1 showed a signiﬁcant reduction in IP7 and a com-
plete absence of more polar inositol polyphosphates, with a marginalreduction in IP6 (Fig. 4E). These cells showed a slight decrease in the
level of PP-IP4 but no change in IP5. Together, our analyses reveal that
lowering IP6K1 expression reduces the level of the more abundant ino-
sitol pyrophosphate - PP-IP4 in HeLa and IP7 in HCT116 cells. The con-
comitant reduction in the level of IP6, while unexpected, is supported
by the high rate of metabolic turnover reported for inositol pyrophos-
phates [1,2], and suggests that cells may evolve compensatory mecha-
nisms in an attempt to maintain the ratio of inositol pyrophosphates
to their precursor inositol polyphosphates.
Depletion of IP6K1 in both HeLa and HCT116 cells resulted in a signif-
icant decrease in chemotactic migration towards serum-rich medium
over a period of 24 h (Fig. 5A–C). A difference in the rate of proliferation
may be reﬂected as an apparent change in transwell migration. To ex-
clude this possibility we performed a cell proliferation assay and did not
observe any signiﬁcant difference in the doubling time of NT and IP6K1
depleted cells (Fig. 4F).We also performed awoundhealing assay on con-
ﬂuent monolayer cultures to look at collective cell migration, and ob-
served reduced migration in IP6K1 depleted HeLa and HCT116 cells
(Fig. 5D–F). Together, our data show that the depletion of IP6K1 lowers
chemotactic and collective migration in these cancer cell lines.
3.5. Depletion of IP6K1 affects the invasive potential of cancer cells
The tumorigenic and metastatic potential of cells depends on their
migratory and invasive properties, which require dramatic reorganiza-
tion of the actin cytoskeleton [40]. Tumorigenicity is further supported
Fig. 4. Characterization of cells expressing shRNA against human IP6K1. (A) Immunoblot to detect IP6K1 in lysates fromHeLa andHCT116 cell lines that stably express the indicated shRNA
(NT, non-targeting control; shIP6K1–1 and shIP6K1–4, two different shRNA sequences directed against human IP6K1). (B, C) The bar graphs represent IP6K1 knockdown levels in HeLa
(B) and HCT116 (C). Data represents mean ± SEM from three independent experiments. (D, E) HPLC proﬁle of [3H] inositol labeled HeLa NT and shIP6K1–4 (D) and HCT116 NT and
shIP6K1–1 (E) cell lines. Soluble inositol phosphate counts were normalized to the total lipid inositol count for each sample. Peaks corresponding to IP5, PP-IP4, IP6 and IP7 are
indicated. Data are representative of two independent experiments. (F) Growth analysis by MTT assay was used to determine the doubling time for HeLa and HCT116 cells stably
expressing the indicated shRNA. Data represents mean ± SEM from three independent experiments and was analyzed using one-way ANOVA with Tukey's multiple comparison test.
The P value was determined to be N0.05 across all comparisons, indicating no signiﬁcant difference in doubling time in cells expressing shIP6K1 compared with NT.
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tion of integrin-growth factor dependent signaling [41]. We therefore
sought to determine the role IP6K1 has on the tumorigenic properties
of cancer cells. We conducted soft-agar growth assays to examine
anchorage-independent growth of cells expressing IP6K1-targeting
shRNA. Depletion of IP6K1 led to a decrease in colony number in both
HCT116 and HeLa cells (Fig. 6A–B). However, there was no effect of
IP6K1 reduction on the size of colonies formed by HeLa or HCT116
cells in soft agar (Fig. 6C–E).We then examined the in vivo tumorigenic
potential of HCT116 cells by subcutaneous injections into the ﬂanks of
athymic nudemice. Interestingly,we did not observe any signiﬁcant dif-
ference in the size of tumors grown from shIP6K1 and NT controls
(Fig. 6F–G). This observation correlates with our ﬁnding that HCT116
cells expressing shIP6K1 show no change in the rate of cell proliferation
or colony size in soft agar.
We explored the invasive property of these cells by a matrigel inva-
sion assay, which mimics early steps in tumor metastasis. IP6K1 deplet-
ed HCT116 cells showed signiﬁcantly reduced invasion compared with
NT control cells (Fig. 7A–B). Matrigel invasion by epithelial cells has
been shown to inversely correlate with the expression of the epithelial
biomarker E-cadherin which promotes cell-cell adhesion [25,42]. We
observed higher levels of E-cadherin in shIP6K1 cells compared withNT cells (Fig. 7C–D), correlating with their reduced invasion potential.
Together, these data suggest that IP6K1maynot play a role in tumor ini-
tiation, but is required for aggressiveness of cancer cells by regulating
anchorage independence, cell migration and invasion.
3.6. Loss of IP6K1 renders mice resistant to 4NQO induced carcinogenesis
To determine if the reduced invasion potential of IP6K1 depleted
cancer cells extends to Ip6k1 knockout cells in vivo we utilized the 4-
nitroquinoline 1-oxide (4NQO) oral squamous cell carcinoma model
[43]. 4NQO is a water-soluble quinoline derivative, which when admin-
istered to mice in drinking water induces a temporal progression of the
different phases of carcinogenesis fromhyperplasia to dysplasia to inva-
sive carcinoma [24,44]. 4NQO treatment of cells has been shown to lead
to their anchorage independence [45], further supporting a potential
role for IP6K1 in 4NQO induced carcinogenesis. After 24 weeks of contin-
uous exposure to 4NQO,we observed 100% survival in both Ip6k1+/+ and
Ip6k1−/−mice. Histopathological examination of tissues from the upper
aerodigestive tract revealed hyperplasia and dysplasia in tongue and
esophagus of both Ip6k1+/+ and Ip6k1−/−mice (Fig. 8A–B). However, in-
vasive carcinoma, deﬁned by the migration of dysplastic epithelial cells
into subepithelial tissues, was less in case of Ip6k1−/−mice, suggesting
Fig. 5. IP6K1 depletion reduces cancer cellmigration. (A) Transwellmigrationwas assessed inNT control and shIP6K1 expressingHeLa (left panel) andHCT116 cells (right panel). Cells that
migrated towards serum-richmedium 24 h after seeding were visualized by staining with DAPI. Scale bars represent 50 μm. (B, C) Quantiﬁcation of (A); the bar graphs show the average
number of cells migrated per ﬁeld in HeLa (B) or HCT116 (C); data represents mean± SEM (n= 127 and 134 ﬁelds respectively for NT control and shIP6K1–4 expressing HeLa; n= 152
and 186 ﬁelds respectively for NT control and shIP6K1–1 expressing HCT116 cells) compiled from three independent experiments and was analyzed using the non-parametric two-tailed
Mann-Whitney test. (D) Scratch wound healing assay on conﬂuent monolayers to monitor collective cell migration in the indicated cell lines. Representative images are shown for the
indicated time points. Black lines overlaid on the images mark the edges of the wound. (E, F) Quantiﬁcation of area covered after 18 h in HeLa (E) or HCT116 (F) cells. Data represents
mean ± SEM from three independent experiments and was analyzed using a two-tailed unpaired Student's t-test. ***P ≤ 0.001; *P ≤ 0.05.
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Taken together, our studies in cells and mice lacking IP6K1 identify a
role for this protein in coordinating multiple cellular events to regulate
cell migration, invasion and carcinogenesis.
4. Discussion
Our study reveals that IP6K1 facilitates the migration and inva-
sion of cancer cells, so that mice lacking IP6K1 show reduced pro-
gression from epithelial dysplasia to invasive carcinoma upon
chronic exposure to an oral carcinogen. At the molecular level, the
absence of IP6K1 brings about changes in gene expression resulting
in the down-regulation of pathways involved in signaling betweenthe cell surface and the extracellular matrix. This leads to deﬁcien-
cies in integrin-mediated signaling events such as FAK and Paxillin
phosphorylation, and defects in actin cytoskeleton remodeling,
resulting in reduced spreading, motility, anchorage-independent
growth and invasion.
Themigration defects we observed in ﬁbroblasts lacking IP6K1were
completely restored upon expression of active but not inactive IP6K1,
suggesting that inositol pyrophosphate synthesis is required to support
cell migration. Migration and invasion are complex cellular responses
that receive inputs from multiple signaling pathways including extra-
cellularmatrix-cell surface signaling, growth factor signaling, actin cyto-
skeleton remodeling, and the secretion of matrix proteases. IP6K1 may
impinge upon some or all of these pathways directly, or act indirectly
Fig. 6. Effect of IP6K1 depletion on tumorigenic potential of cancer cells. (A) Anchorage-independent growth of cells seeded in soft agar was determined after 3 weeks by staining with
crystal violet to visualize and count the number of colonies. Representative images of crystal violet stained colonies are shown. (B) Bar graph shows the number of colonies per dish in
IP6K1 depleted HeLa and HCT116 cells normalized to their respective NT controls. Data are mean ± SEM from three independent experiments and were analyzed by a one-sample t-
test. (C) Colonies formed in soft agar (A) were imaged at higher magniﬁcation as described in the Methods section. (D, E) Bar graphs showing the colony sizes obtained after growth
of HeLa (D) and HCT116 (E) cells for 3 weeks in soft agar (n = 66 and 67 for HeLa NT control and shIP6K1–4 respectively; n = 63 and 52 for HCT116 NT control and shIP6K1–1 respec-
tively). Data (mean±SEM)are representative of two independent experiments andwere analyzed using the non-parametric two-tailedMann-Whitney test. (F) Subcutaneous xenografts
of HCT116 NT (top row) and shIP6K1–1 (bottom row) cells, isolated 4weeks after injection of cells into either ﬂank of the samemouse. (G) Symbol and line plot displaying theweights of
tumors derived fromHCT116NT and shIP6K1–1 cells. Symbols indicate the tumorweight scatter, and lines represent the pair-wise analysis of tumors isolated from either ﬂank of the same
mouse (n = 8). Data was analyzed using a two-tailed paired Student's t-test. **P ≤ 0.01; *P ≤ 0.05; ns, not signiﬁcant, P ≥ 0.05.
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phosphate kinase family has been shown to regulate mRNA transcrip-
tion and export via the synthesis of nuclear PI(3,4,5)P3, inﬂuence epige-
netic regulation via its product I(1,4,5,6)P4, and also act directly as a
transcriptional co-activator in an enzyme-independent manner [46].
Similarly, IP6K1 could regulate gene expression via the synthesis of ino-
sitol pyrophosphates or by directly interacting with other proteins. Ino-
sitol pyrophosphates have been shown to control the activity of the
histone deacetylase Rpd3L in yeast [47] and the histone demethylase
JMJD2C in mammals [48] to regulate chromatin remodeling. The inosi-
tol pyrophosphate 1-IP7 has been shown to activate the mammalian
transcription factor IRF3 [49]. Inositol pyrophosphates synthesized by
IP6K1 could also act in a similarmanner, inﬂuencing the activity of tran-
scription regulatory proteins via serine pyrophosphorylation or binding.
Inositol pyrophosphates synthesized by IP6K1 have been shown to
play an important role in maintaining genomic integrity by promoting
DNA repair through homologous recombination [12] and nucleotide ex-
cision repair pathways [13], suggesting that mice lacking Ip6k1may ex-
hibit a propensity to develop spontaneous tumors. However, gross and
microscopic examination of liver, kidney, spleen, thymus and lymph
nodes from four individual 2 year old male Ip6k1+/+ and Ip6k1−/−
mice revealed no lesions, suggesting that the loss of IP6K1 does not re-
sult in spontaneous tumor formation. Despite their overlapping expres-
sion pattern and high degree of sequence identity, IP6K1 and IP6K2have several distinct cellular and physiological functions. IP6K1 pro-
motes insulin secretion from pancreatic beta cells [11] andmice lacking
IP6K1 display reduced levels of serum insulin [14], whereas IP6K2
knockout mice have normal insulin levels [21]. Male mice lacking
IP6K1 are sterile [14] whereas IP6K2 knockoutmice show normal fertil-
ity [21]. At the cellular level, MEFs derived from Ip6k1−/− mice
displayed a 70% reduction in IP7 levels [14] whereas Ip6k2−/− MEFs
showed a 20 to 30% reduction [20,21], suggesting that IP6K1 is the
major IP7 synthesizing enzyme in these cells. HCT116 cells have been
shown to possess very high levels of inositol pyrophosphates [50]. The
deletion of IP6K2 in these cells leads to an almost complete loss of IP7
[19], whereas we observe that depletion of IP6K1 also results in a de-
crease in IP7 levels (Fig. 4E), suggesting that both IP6K1 and IP6K2 con-
tribute to IP7 pools in HCT116 cells.
Recently, it was shown that HCT116 cells lacking IP6K2 display de-
fects in cell adhesion andmigration, resulting in reduced tumor growth
andmetastasis when these cells are implanted in immunocompromised
mice [18]. Complementation with the active but not the inactive en-
zyme was able to reverse defects in cell migration and tumor growth,
suggesting that inositol pyrophosphates are essential for these process-
es. Althoughwe also observe reducedmigration and invasion properties
in IP6K1 depleted HCT116 cells, there is no reduction in tumor volume.
We speculate that the threshold level of inositol pyrophosphates re-
quired to support cell migration is higher than the level required for
Fig. 7. IP6K1modulates the invasive potential of cancer cells. (A) HCT116 cells stably expressing NT or shIP6K1–1were allowed to invade amatrigelmatrix tomove towards a high-serum
gradient for 24 h. Representative images show cells that migrated through the gel to the other side of the membrane, visualized by staining with DAPI. Scale bars represent 50 μm.
(B) Quantiﬁcation of (A); bar graphs show the number of invaded cells normalized to the NT control. Data are mean ± SEM from ﬁve independent experiments, and were analyzed by
a one sample t-test. (C) Immunoblot analysis of epithelial marker E-Cadherin in HCT116 cells expressing NT or shIP6K1–1. (D) Quantiﬁcation of (C); levels of the epithelial marker E-
cadherin are indicated as a ratiowith respect to the levels of GAPDHwhichwas the loading control. Data representsmean± SEM from three independent experiments andwas analyzed
using a two tailed unpaired Student's t-test. **P ≤ 0.01; ***P ≤ 0.001.
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HCT116 cells is sufﬁcient to result in migration and invasion defects
but not enough to cause a decrease in tumor volume, whereas the
near complete loss of IP7 in IP6K2 knockout HCT116 cells affects both
these processes [18]. The distinct functions of IP6K1 and IP6K2 in
tumor development may also arise from their differential effects on
cell proliferation, with IP6K2 knockout HCT116 cells exhibiting delayed
growth [18], and IP6K1 depleted cells exhibiting no change in doubling
time (Fig. 4F).
Although HCT116 cells lacking IP6K2 show reduced tumor develop-
ment [18], mice lacking IP6K2 show accelerated development of inva-
sive aerodigestive tract epithelial carcinoma upon being fed the oral
carcinogen 4NQO [21]. This was attributed primarily to the apoptosis-
enhancing functions of IP6K2 as well as to overexpression of oncogenes
and loss of tumor suppressors in Ip6k2 knockout tissues. Our results
upon feeding the same carcinogen to Ip6k1 knockout mice revealed
that unlike IP6K2, the loss of IP6K1 protects them from invasive carcino-
ma, underlining the fact that IP6K1 and IP6K2 have distinct roles in car-
cinogenesis. One possible reason for this divergence between the
functions of IP6K1 and IP6K2 is that the loss of IP6K2 but not IP6K1
has been shown to render cells resistant to apoptosis [51]. Another rea-
son could be distinct patterns of gene expression in Ip6k1 versus Ip6k2
knockout mice. The alterations in expression of oncogenes and tumor
suppressors identiﬁed in Ip6k2 knockout tissues [21] may not be con-
served in Ip6k1 knockout mice. Taken together, these studies reveal
that in aerodigestive tract epithelial cells it is IP6K1 that is responsible
for carcinogenesis, whereas the dominant function of IP6K2 is to protect
cells from transformation. Therefore, the development of an isoform-
speciﬁc IP6K1 inhibitor may provide a novel route to prevent the pro-
gression of epithelial dysplasia to invasive carcinoma.5. Conclusions
In the present study we demonstrate the importance of IP6K1 in
adhesion-dependent signaling pathways controlling cell spreading
and migration. Cancer cells deﬁcient in IP6K1 show decreased anchor-
age independent growth, migration and invasion. Mice lacking IP6K1
are protected from invasive carcinoma induced by an oral carcinogen,
suggesting that IP6K1 inhibition may provide a novel path to suppress
cancer progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2016.04.011.
Author contributions
RSJ conducted most of the experiments, analyzed the results, and
wrotemost of the paper. DK andNBu conducted experiments on cell ad-
hesion and spreading. SG performed RT-qPCR analysis and E-caherin
Western blot analysis. SRT performed inositol polyphosphate determi-
nation experiments. NBa provided expertise on cell surface-ECM signal-
ing and cell spreading. RB conceived and coordinated the study and
wrote the paper with NBa and RSJ. All the authors read and approved
the ﬁnal version of the manuscript.
Funding information
This work was supported by a Senior Fellowship from the Wellcome
Trust/Department of Biotechnology India Alliance (WT/DBT IA, 500020/
Z/09/Z to R.B.) and Centre for DNA Fingerprinting and Diagnostics core
funds. R.S.J. and S.R.T. are recipients of Junior and Senior Research Fellow-
ships from the Council of Scientiﬁc and Industrial Research and the
Fig. 8. IP6K1 knockout rendersmice resistance to 4NQO induced carcinogenesis. Ip6k1+/+ and Ip6k1−/−micewere administered the oral carcinogen 4NQO in drinkingwater continuously
for 24 weeks. (A) Representative images of H&E stained tissues show the normal epithelium of the tongue and esophagus of untreated Ip6k1+/+ mice (left panel), induction of invasive
carcinoma in the tongue and esophagus of Ip6k1+/+mice (middle panel), and the same tissues in Ip6k1−/− revealing dysplasia and hyperplasia (right panel). Scale bars represent 100 μm.
(B) Stacked bars represent the percentage of different types of lesions observed in mice of the indicated genotypes. n = 11 and 9 for Ip6k1+/+ and Ip6k1−/−mice respectively.
1135R.S. Jadav et al. / Cellular Signalling 28 (2016) 1124–1136Department of Biotechnology, Government of India, respectively. N·Ba
acknowledges funding from a WT/DBT IA Senior Fellowship
(WT_DBT_30711059).
Conﬂict of interest
The authors declare that they have no conﬂicts of interest with the
contents of this article.
Acknowledgements
We thank Mohamed Aiyaz and others at Genotypic Technology Pvt.
Ltd. for conducting the microarray analysis and uploading the data.
Dr. Jomy Jose for examining tissue pathology and categorizing lesions.
We thank Somadri Ghosh and Dhananjay Shukla for their contribution
to microarray data analysis; Joy P. Vallentyne, Suman Komjeti and
Sridhar Kavela for technical assistance; Murali Bashyam, Shweta Tyagi,
and members of the Laboratory of Cell Signalling for valuable feedback.
The microarray data discussed in this manuscript have been depos-
ited in NCBI's Gene Expression Omnibus [52] and are accessible through
GEO Series accession number GSE73612 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE73612).
References
[1] F.S. Menniti, R.N. Miller, J.W. Putney Jr., S.B. Shears, Turnover of inositol polyphosphate
pyrophosphates in pancreatoma cells, J. Biol. Chem. 268 (6) (1993) 3850–3856.
[2] L. Stephens, T. Radenberg, U. Thiel, G. Vogel, K.H. Khoo, A. Dell, et al., The detection,
puriﬁcation, structural characterization, and metabolism of diphosphoinositol
pentakisphosphate(s) and bisdiphosphoinositol tetrakisphosphate(s), J. Biol.
Chem. 268 (6) (1993) 4009–4015.[3] M.S. Wilson, T.M. Livermore, A. Saiardi, Inositol pyrophosphates: between signalling
and metabolism, Biochem. J. 452 (3) (2013) 369–379.
[4] S.G. Thota, R. Bhandari, The emerging roles of inositol pyrophosphates in eukaryotic
cell physiology, J. Biosci. 40 (3) (2015) 593–605.
[5] R. Bhandari, A. Saiardi, Y. Ahmadibeni, A.M. Snowman, A.C. Resnick, T.Z. Kristiansen,
et al., Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational
event, Proc. Natl. Acad. Sci. U. S. A. 104 (39) (2007) 15305–15310.
[6] A. Chakraborty, S. Kim, S.H. Snyder, Inositol pyrophosphates as mammalian cell sig-
nals, Sci. Signal. 4 (188) (2011) re1.
[7] A. Saiardi, H. Erdjument-Bromage, A.M. Snowman, P. Tempst, S.H. Snyder, Synthesis
of diphosphoinositol pentakisphosphate by a newly identiﬁed family of higher ino-
sitol polyphosphate kinases, Curr. Biol. 9 (22) (1999) 1323–1326.
[8] M.P. Thomas, B.V. Potter, The enzymes of human diphosphoinositol polyphosphate
metabolism, FEBS J. 281 (1) (2014) 14–33.
[9] A. Saiardi, E. Nagata, H.R. Luo, A.M. Snowman, S.H. Snyder, Identiﬁcation and charac-
terization of a novel inositol hexakisphosphate kinase, J. Biol. Chem. 276 (42) (2001)
39179–39185.
[10] M. Bennett, S.M. Onnebo, C. Azevedo, A. Saiardi, Inositol pyrophosphates: metabo-
lism and signaling, Cell. Mol. Life Sci. 63 (5) (2006) 552–564.
[11] C. Illies, J. Gromada, R. Fiume, B. Leibiger, J. Yu, K. Juhl, et al., Requirement of inositol
pyrophosphates for full exocytotic capacity in pancreatic cells, Science 318 (5854)
(2007) 1299–1302.
[12] R.S. Jadav, M.V. Chanduri, S. Sengupta, R. Bhandari, Inositol pyrophosphate synthesis
by inositol hexakisphosphate kinase 1 is required for homologous recombination re-
pair, J. Biol. Chem. 288 (5) (2013) 3312–3321.
[13] F. Rao, J. Xu, A.B. Khan, M.M. Gadalla, J.Y. Cha, R. Xu, et al., Inositol hexakisphosphate
kinase-1 mediates assembly/disassembly of the CRL4-signalosome complex to reg-
ulate DNA repair and cell death, Proc. Natl. Acad. Sci. U. S. A. 111 (45) (2014)
16005–16010.
[14] R. Bhandari, K.R. Juluri, A.C. Resnick, S.H. Snyder, Gene deletion of inositol
hexakisphosphate kinase 1 reveals inositol pyrophosphate regulation of insulin se-
cretion, growth, and spermiogenesis, Proc. Natl. Acad. Sci. U. S. A. 105 (7) (2008)
2349–2353.
[15] S. Ghosh, D. Shukla, K. Suman, B.J. Lakshmi, R. Manorama, S. Kumar, et al., Inositol
hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet
polyphosphate levels, Blood 122 (2013) 1478–1486.
[16] A. Chakraborty, M.A. Koldobskiy, N.T. Bello, M. Maxwell, J.J. Potter, K.R. Juluri, et al.,
Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity
and weight gain, Cell 143 (6) (2010) 897–910.
1136 R.S. Jadav et al. / Cellular Signalling 28 (2016) 1124–1136[17] A. Chakraborty, C. Latapy, J. Xu, S.H. Snyder, J.M. Beaulieu, Inositol hexakisphosphate
kinase-1 regulates behavioral responses via GSK3 signaling pathways, Mol. Psychia-
try 19 (3) (2014) 284–293.
[18] F. Rao, J. Xu, C. Fu, J.Y. Cha, M.M. Gadalla, R. Xu, et al., Inositol pyrophosphates pro-
mote tumor growth andmetastasis by antagonizing liver kinase B1, Proc. Natl. Acad.
Sci. U. S. A. 112 (6) (2015) 1773–1778.
[19] M.A. Koldobskiy, A. Chakraborty, J.K. Werner Jr., A.M. Snowman, K.R. Juluri, M.S.
Vandiver, et al., p53-mediated apoptosis requires inositol hexakisphosphate
kinase-2, Proc. Natl. Acad. Sci. U. S. A. 107 (49) (2010) 20947–20951.
[20] F. Rao, J. Cha, J. Xu, R. Xu, M.S. Vandiver, R. Tyagi, et al., Inositol pyrophosphates me-
diate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation
of Tti1/Tel2, Mol. Cell 54 (1) (2014) 119–132.
[21] B.H. Morrison, R. Haney, E. Lamarre, J. Drazba, G.D. Prestwich, D.J. Lindner, Gene de-
letion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract car-
cinoma, Oncogene 28 (25) (2009) 2383–2392.
[22] C. Fu, J. Xu, R.J. Li, J.A. Crawford, A.B. Khan, T.M. Ma, et al., Inositol hexakisphosphate
kinase-3 regulates the morphology and synapse formation of cerebellar purkinje
cells via spectrin/adducin, J. Neurosci. 35 (31) (2015) 11056–11067.
[23] J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer: biological implications and ther-
apeutic opportunities, Nat. Rev. Cancer 10 (1) (2010) 9–22.
[24] X.H. Tang, B. Knudsen, D. Bemis, S. Tickoo, L.J. Gudas, Oral cavity and esophageal car-
cinogenesis modeled in carcinogen-treated mice, Clin. Cancer Res. 10 (1 Pt 1)
(2004) 301–313.
[25] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (5)
(2011) 646–674.
[26] T.D. Schmittgen, K.J. Livak, Analyzing real-time PCR data by the comparative
C(T) method, Nat. Protoc. 3 (6) (2008) 1101–1108.
[27] D.C. Hocking, J. Sottile, P.J. McKeown-Longo, Activation of distinct alpha5beta1-
mediated signaling pathways by ﬁbronectin's cell adhesion and matrix assembly
domains, J. Cell Biol. 141 (1) (1998) 241–253.
[28] N. Balasubramanian, J.A. Meier, D.W. Scott, A. Norambuena, M.A. White, M.A.
Schwartz, RalA-exocyst complex regulates integrin-dependent membrane raft exo-
cytosis and growth signaling, Curr. Biol. 20 (1) (2010) 75–79.
[29] C. Azevedo, A. Saiardi, Extraction and analysis of soluble inositol polyphosphates
from yeast, Nat. Protoc. 1 (5) (2006) 2416–2422.
[30] K.A. Bowen, H.Q. Doan, B.P. Zhou, Q. Wang, Y. Zhou, P.G. Rychahou, et al., PTEN loss
induces epithelial–mesenchymal transition in human colon cancer cells, Anticancer
Res. 29 (11) (2009) 4439–4449.
[31] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large
gene lists using DAVID bioinformatics resources, Nat. Protoc. 4 (1) (2009) 44–57.
[32] D.S. Harburger, D.A. Calderwood, Integrin signalling at a glance, J. Cell Sci. 122 (Pt 2)
(2009) 159–163.
[33] K.R. Legate, S.A.Wickstrom, R. Fassler, Genetic and cell biological analysis of integrin
outside-in signaling, Genes Dev. 23 (4) (2009) 397–418.
[34] L.S. Price, J. Leng, M.A. Schwartz, G.M. Bokoch, Activation of Rac and Cdc42 by
integrins mediates cell spreading, Mol. Biol. Cell 9 (7) (1998) 1863–1871.
[35] S.K. Hanks, M.B. Calalb, M.C. Harper, S.K. Patel, Focal adhesion protein-tyrosine ki-
nase phosphorylated in response to cell attachment to ﬁbronectin, Proc. Natl.
Acad. Sci. U. S. A. 89 (18) (1992) 8487–8491.[36] M.D. Schaller, J.D. Hildebrand, J.D. Shannon, J.W. Fox, R.R. Vines, J.T. Parsons, Auto-
phosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent
binding of pp60src, Mol. Cell. Biol. 14 (3) (1994) 1680–1688.
[37] T.S. Panetti, Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell
spreading and migration, Front. Biosci. 7 (2002) d143–d150.
[38] S.L. Bellis, J.A. Perrotta, M.S. Curtis, C.E. Turner, Adhesion of ﬁbroblasts to ﬁbronectin
stimulates both serine and tyrosine phosphorylation of paxillin, Biochem. J. 325 (Pt
2) (1997) 375–381.
[39] N.O. Deakin, C.E. Turner, Paxillin comes of age, J. Cell Sci. 121 (Pt 15) (2008)
2435–2444.
[40] M. Yilmaz, G. Christofori, EMT, the cytoskeleton, and cancer cell invasion, Cancer
Metastasis Rev. 28 (1–2) (2009) 15–33.
[41] M.A. Schwartz, Integrins, oncogenes, and anchorage independence, J. Cell Biol. 139
(3) (1997) 575–578.
[42] A. Jeanes, C.J. Gottardi, A.S. Yap, Cadherins and cancer: how does cadherin dysfunc-
tion promote tumor progression? Oncogene 27 (55) (2008) 6920–6929.
[43] B.L. Hawkins, B.W. Heniford, D.M. Ackermann, M. Leonberger, S.A. Martinez, F.J.
Hendler, 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcino-
ma, Head Neck 16 (5) (1994) 424–432.
[44] J.F.Wilkey, G. Buchberger, K. Saucier, S.M. Patel, E. Eisenberg, H. Nakagawa, et al., Cy-
clin D1 overexpression increases susceptibility to 4-nitroquinoline 1-oxide induced
dysplasia and neoplasia in murine squamous oral epithelium, Mol. Carcinog. 48 (9)
(2009) 853–861.
[45] I.J. Crane, J. Luker, L. de Gay, S.Q. Rice, A. Stone, C. Scully, et al., Transformation of oral
keratinocytes in vitro by 4-nitroquinoline N-oxide, Carcinogenesis 9 (12) (1988)
2251–2256.
[46] E. Kim, J. Beon, S. Lee, J. Park, S. Kim, IPMK: a versatile regulator of nuclear signaling
events, Adv. Biol. Regul. (2015).
[47] J. Worley, X. Luo, A.P. Capaldi, Inositol pyrophosphates regulate cell growth and the
environmental stress response by activating the HDAC Rpd3L, Cell Rep. 3 (5) (2013)
1476–1482.
[48] A. Burton, C. Azevedo, C. Andreassi, A. Riccio, A. Saiardi, Inositol pyrophosphates reg-
ulate JMJD2C-dependent histone demethylation, Proc. Natl. Acad. Sci. U. S. A. 110
(47) (2013) 18970–18975.
[49] N.K. Pulloor, S. Nair, A.D. Kostic, P. Bist, J.D. Weaver, A.M. Riley, et al., Human
genome-wide RNAi screen identiﬁes an essential role for inositol pyrophosphates
in Type-I interferon response, PLoS Pathog. 10 (2) (2014), e1003981.
[50] M.S. Wilson, S.J. Bulley, F. Pisani, R.F. Irvine, A. Saiardi, A novel method for the puri-
ﬁcation of inositol phosphates from biological samples reveals that no phytate is
present in human plasma or urine, Open Biol. 5 (3) (2015) 150014.
[51] E. Nagata, H.R. Luo, A. Saiardi, B.I. Bae, N. Suzuki, S.H. Snyder, Inositol
hexakisphosphate kinase-2, a physiologic mediator of cell death, J. Biol. Chem. 280
(2) (2005) 1634–1640.
[52] R. Edgar, M. Domrachev, A.E. Lash, Gene expression omnibus: NCBI gene expression
and hybridization array data repository, Nucleic Acids Res. 30 (1) (2002) 207–210.
